spatial transcriptomics visium data (Spatial Transcriptomics Inc)
Structured Review

Spatial Transcriptomics Visium Data, supplied by Spatial Transcriptomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/spatial transcriptomics visium data/product/Spatial Transcriptomics Inc
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma"
Article Title: Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma
Journal: Cell Reports Medicine
doi: 10.1016/j.xcrm.2025.102188
Figure Legend Snippet: EAC primary and metastatic samples show a diverse landscape of TME and malignant cells in transcriptomic and epigenetic data (A) Schematic representation of the study workflow. Biopsies from 10 patients in our discovery cohort, including normal adjacent tissue (NAT), primary tissue, and metastatic samples, were subjected to single-nuclei RNA and ATAC sequencing using 10X Chromium technology. For a subset of these patients as well as three additional patients, matched primary and metastatic samples were profiled with 10X Visium and 10X Xenium spatial transcriptomics (ST) technologies. For single-nuclei data, cells were annotated by cell type and categorized into malignant and TME components. TME subtypes were linked to metastasis, with validation against an external pan-cancer fibroblast atlas. The malignant cell components underwent analysis using consensus non-negative matrix factorization (cNMF) to uncover malignant programs, which were further characterized for transcriptional and epigenetic heterogeneity at a single-cell and spatial level and candidate master transcription factors. External validation was performed in two single-cell validation cohorts, , and associations with clinical and molecular characteristics, as well as survival, were assessed in three bulk validation cohorts. , , (B) Uniform manifold approximation and projection (UMAP) representation of the full cohort in Harmony-corrected integrated transcriptomic data, with major cell type compartments labeled and cell counts indicated. (C) Proportion of major cell types in each sample based on transcriptomic data, with percentages for compartments representing over 5% of the total sample composition. (D) UMAP representation of the full cohort in Harmony-corrected integrated ATAC data, with cell type annotations transferred from the RNA annotations. “NA” denotes cells without paired associated RNA information. (E) Proportion of major cell types in each sample based on ATAC data, with percentages for compartments representing over 5% of the total sample composition.
Techniques Used: Sequencing, Biomarker Discovery, Labeling
Figure Legend Snippet: Single-nuclei-derived transcriptional programs highlight different spatial regions of EAC tumors (A) Spatial transcriptomics (ST) slides of P8 primary tumor A, colored according to cNMF program score and the CNV-derived label. For each spot, we infer the CNV profile with inferCNV and assign spots to tumor, mixed, and normal status. cNMF scores are computed as the average Z score of signature genes using the deconvolved carcinoma-specific gene expression profile of spots derived with Cell2Location. (B) Average cNMF score according to the position of the spots compared to the tumor-leading edge. For each tumor spot, we compute the distance to the edge as the shortest path to a normal or mixed spot. The distribution of cNMF scores with standard error is represented for normal spots, mixed spots, and spots of a certain distance to the edge. (C) cNMF scores for carcinoma cells and cell type annotations in a subset of Xenium-profiled samples (P4_A, P11_B, and P12_D). cNMF scores are computed as the average Z score across all carcinoma cells of signature genes included in the Xenium panel. (D) CellCharter cluster assignments for a subset of Xenium-profiled samples (P4_A, P11_B, and P12_D). (E) CellCharter cluster cell type proportion: each cell is assigned a cluster and we represent the proportion of the different cell types in each of the CellCharter clusters. (F) Distribution of cNMF scores of carcinoma cells belonging to the CellCharter clusters with a substantial amount of carcinoma cells (>5%), CC1, CC2, CC3, and CC4. For all comparisons, Mann-Whitney U p < 0.000005.
Techniques Used: Derivative Assay, Gene Expression, MANN-WHITNEY
